Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss
OBJECTIVES: I. Determine the effect of megestrol and progressive resistance training on lean
body mass, total body weight, functional capacity, appetite, and fatigue in patients with
weight loss due to advanced malignancy.
OUTLINE: This is a multicenter study. Patients receive oral megestrol once daily. Patients
also begin progressive resistance training 3 days a week. Treatment/exercise continues for
12 weeks in the absence of unacceptable toxicity or progressive weight loss (greater than 5
pounds or 5% or more over first 4 study weeks).
PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study within 1 year.
Interventional
Primary Purpose: Supportive Care
Jamie Hayden Von Roenn, MD
Study Chair
Robert H. Lurie Cancer Center
United States: Federal Government
NU FDA98CC6
NCT00004912
January 2000
November 2003
Name | Location |
---|---|
Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago, Illinois 60611 |
Shands Hospital and Clinics, University of Florida | Gainesville, Florida 32610-100277 |
Rex Healthcare | Raleigh, North Carolina 27607 |
Pacific Shores Medical Group | Long Beach, California 90813 |
University of Arkansas - Department of Geriatrics | North Little Rock, Arkansas 72114-1706 |
Office of David Cella | Evanston, Illinois 60201 |